Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Follitropin alfa - Merck Serono

Drug Profile

Follitropin alfa - Merck Serono

Alternative Names: Follitropin-alpha; GONAL-f; GONAL-f RFF Redi-ject; Gonalef; Recombinant human follicle-stimulating hormone - Merck Serono; recombinant human follicle-stimulating hormone - Serono; rh-FSH; rhFSH - Merck Serono; rhFSH - Serono; SJ-0021

Latest Information Update: 18 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck Serono
  • Developer EMD Serono; Merck Serono; Nippon Shinyaku
  • Class Follicle stimulating hormones; Infertility therapies; Peptide fragments; Pituitary gonadotropins; Recombinant proteins
  • Mechanism of Action Chorionic gonadotropin stimulants; Ovarian follicle stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Male infertility
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Female infertility; Male infertility

Most Recent Events

  • 06 Dec 2018 Merck Serono completes a trial for Female infertility in Japan (UMIN000015669)
  • 13 Nov 2017 The US FDA approves follitropin alfa injection prefilled pen for treatment of Infertility in USA
  • 01 Jul 2015 Follitropin alfa licensed to Nippon Shinyaku in Japan for Male infertility and Female infertility
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top